Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ravi Shankar

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Journal of Clinical & Translational Endocrinology|February 22, 2019
Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomesJuan José Gagliardino, Rosario Arechavaleta, Freddy Goldberg Eliaschewitz, et al.
Gastro Hep Advances|July 21, 2025
Risk Prediction in Patients With Metabolic Dysfunction-Associated Steatohepatitis Using Natural Language ProcessingJordan Guillot, Christopher Y K Williams, Shadera Azzam, et al.
International Journal of Clinical Practice|May 26, 2017
Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database studyTim Holbrook, Yuexin Tang, Romita Das, et al.
American Journal of Physiology. Endocrinology and Metabolism|April 14, 2016
Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation seriesSudha S Shankar, R Ravi Shankar, Lori A Mixson, et al.
Journal of Diabetes Investigation|May 17, 2016
Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitusLinong Ji, Ping Han, Xiaoyue Wang, et al.
Current Medical Research and Opinion|December 31, 2016
A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose aloneWeiqing Wang, Guang Ning, Jianhua Ma, et al.
Diabetes, Obesity & Metabolism|November 6, 2018
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I StudyRonan Roussel, Santiago Duran-García, Yilong Zhang, et al.
The Journal of Clinical Endocrinology and Metabolism|March 11, 2022
Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic HypogonadismR Ravi Shankar, Suneri Shah, Hee-Koung Joeng, et al.
Diabetes|March 17, 2018
Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 DiabetesSudha S Shankar, R Ravi Shankar, Lori A Mixson, et al.
Pediatric Diabetes|November 15, 2021
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulinMuhammad Yazid Jalaludin, Asma Deeb, Philip Zeitler, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of Clinical & Translational Endocrinology|February 22, 2019
Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomesJuan José Gagliardino, Rosario Arechavaleta, Freddy Goldberg Eliaschewitz, et al.
Gastro Hep Advances|July 21, 2025
Risk Prediction in Patients With Metabolic Dysfunction-Associated Steatohepatitis Using Natural Language ProcessingJordan Guillot, Christopher Y K Williams, Shadera Azzam, et al.
International Journal of Clinical Practice|May 26, 2017
Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database studyTim Holbrook, Yuexin Tang, Romita Das, et al.
American Journal of Physiology. Endocrinology and Metabolism|April 14, 2016
Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation seriesSudha S Shankar, R Ravi Shankar, Lori A Mixson, et al.
Journal of Diabetes Investigation|May 17, 2016
Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitusLinong Ji, Ping Han, Xiaoyue Wang, et al.
Current Medical Research and Opinion|December 31, 2016
A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose aloneWeiqing Wang, Guang Ning, Jianhua Ma, et al.
Diabetes, Obesity & Metabolism|November 6, 2018
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I StudyRonan Roussel, Santiago Duran-García, Yilong Zhang, et al.
The Journal of Clinical Endocrinology and Metabolism|March 11, 2022
Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic HypogonadismR Ravi Shankar, Suneri Shah, Hee-Koung Joeng, et al.
Diabetes|March 17, 2018
Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 DiabetesSudha S Shankar, R Ravi Shankar, Lori A Mixson, et al.
Pediatric Diabetes|November 15, 2021
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulinMuhammad Yazid Jalaludin, Asma Deeb, Philip Zeitler, et al.
Pageof 5